NCI-H1355細(xì)胞

年限： stage 4

器官來源： 肺

是否是腫瘤細(xì)胞： 0

物種來源： 人

運(yùn)輸方式： 凍存運(yùn)輸

數(shù)量： 大量

生長狀態(tài)： 懸浮生長

ATCC Number： CRL-5865?

相關(guān)**： 腺癌

Designations: NCI-H1355 [H1355]

Depositors: AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Homo sapiens

NCI-H1355細(xì)胞Morphology:

Source: Organ: lung

Tumor Stage: stage 4

Disease: adenocarcinoma

Derived from metastatic site: pleural effusion

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. NCI-H1355細(xì)胞Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

Isolation: Bethesda Maryland,

Isolation date: March, 1986

DNA Profile (STR): Amelogenin: X

CSF1PO: 12,13

D13S317: 12

D16S539: 8,13

D5S818: 11,13

D7S820: 12

THO1: 9

TPOX: 9,12

vWA: 14,17

Cytogenetic Analysis: modal number = 54; range = 43-66

Age: 53 years

Gender: male

Ethnicity: Caucasian

Propagation: ATCC complete growth medium: ACL-4 medium (serum-free)

The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:

0.02 mg/ml insulin

0.01 mg/ml transferrin

NCI-H1355細(xì)胞25 nM sodium selenite (final conc.)

50 nM Hydrocortisone (final conc.)

1 ng/ml Epidermal Growth Factor (do not filter)

0.01 mM ethanolamine (final conc.)

0.01 mM phosphorylethanolamine (final conc.)

100 pM triiodothyronine (final conc.)

0.5% (w/v) bovine serum albumin (final conc.)

0.5 mM sodium pyruvate (final conc.)

extra 2mM L-glutamine (for final conc. of 4.5mM)

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Growth Conditions: Add fresh medium as the cell density increases.

Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or by replacement of medium. Alternatively, cultures can be established by centrifugation and subsequent resuspension of the pellet. The cells grow in floating aggregates of round cell clusters.

Medium Renewal: twice weekly

Preservation: Freeze medium: Complete culture medium, 85%; fetal bovine serum, 10%; DMSO, 5%

Storage temperature: liquid nitrogen vapor phase

Related Products: Recommended medium NCI-H1355細(xì)胞(without the additional supplements or serum described under ATCC Medium):ATCC 30-2006

References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.